This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Angiotech Rises on Patent Win

Shares of Angiotech Pharmaceuticals (ANPI) gained 5.5% after a Dutch court ruled in favor of the company and partner Boston Scientific (BSX - Get Report) in a patent dispute with Conor Medsystems (CONR).

Angiotech gained 47 cents to $9.07 Wednesday morning.

The lawsuit claims that Conor's CoStar drug-eluting stent infringes a patent held by Angiotech in Europe. The devices are used to prop open arteries cleared of plaque. The patent is part of a worldwide patent portfolio exclusively licensed to Boston Scientific.

"This is a significant victory in a key area of our intellectual property," said Angiotech. "Conor's attempt to design around our patented technology has failed. Not only did the court uphold Angiotech's patent rights in the Netherlands, it also ruled that Conor's stent infringes upon that intellectual property."

Angiotech expects reviews and hearings on the patent claims to continue and says Conor is likely to appeal the court decision.

Conor fell 7 cents to $32.86 and Boston Scientific dropped 8 cents to $18.04.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BSX $16.84 4.80%
AAPL $94.80 -0.22%
FB $101.26 1.50%
GOOG $690.46 1.10%
TSLA $152.13 2.80%


Chart of I:DJI
DOW 16,022.05 -5.00 -0.03%
S&P 500 1,852.33 -1.11 -0.06%
NASDAQ 4,283.4940 -0.2590 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs